An international collaboration spearheaded by researchers from University College London (UCL), Great Ormond Street Hospital (GOSH), and KU Leuven is delving into groundbreaking solutions for a critical pediatric condition known as congenital diaphragmatic hernia (CDH). This condition, which affects approximately one in 3,000 newborns, presents a significant challenge due to the underdevelopment of the diaphragm, the crucial muscle that separates the chest cavity from the abdomen. The implications of CDH are serious; failing to develop fully can lead to the compression of developing lungs, significantly impacting a baby’s capacity to breathe after birth.
In extreme cases, the prognosis for babies born with unaddressed CDH is dismal, with survival rates plummeting below 25%. The current medical interventions are often surgical and can necessitate complex maneuvers inside the womb. One such technique, known as fetoscopic tracheal occlusion (FETO), involves the intricate placement of a surgical balloon within the fetus’s trachea, with the intent of stimulating lung growth by generating pressure within the chest cavity. While FETO has been shown to enhance survival rates to about 50%, there remains a pressing need for more effective and less invasive treatment options.
Emerging from recent studies is an innovative approach utilizing vascular endothelial growth factor (VEGF), a potent hormone essential for promoting lung development. It has been observed that levels of VEGF are markedly diminished in the lungs of babies suffering from CDH. To mitigate this inadequacy, the research team attached VEGF molecules to a unique microscopic delivery system made from nanodiamonds—sophisticated carbon nanoparticles on a nanoscale, thinner than a human hair. This intricate invention, developed chiefly at the Zayed Centre for Research, aims to deliver a controlled and sustained release of VEGF directly to the lungs of the affected fetus, fostering an environment that promotes healthy lung development before birth.
Preliminary assessments of this VEGF delivery system have utilized lab-grown “mini lungs” that emulate the key characteristics of CDH, alongside various animal models that replicate the condition. Through these engagements, the researchers established that simultaneous administration of the VEGF delivery system along with FETO yielded significantly improved lung health outcomes in their subjects. They evaluated several comparison scenarios and arrived at compelling evidence that substantiates their hypothesis.
The modeling of CDH was taken a step further when the research teams engaged in 3D printing techniques to create an environment that mimicked the disease’s respiratory disruptions. By encasing human tissue cultivated in laboratories, they could replicate the compression conditions affecting the lungs of babies diagnosed with CDH. The design of these miniaturized lung models is pivotal in testing the VEGF delivery system’s efficacy, proving invaluable in preclinical trials aimed at optimizing treatment methods.
Dr. Stavros Loukogeorgakis, a co-lead author and a pediatric surgeon at GOSH, noted the innovative blend of technology and biology in the research. He stated, “While it may seem like science fiction, the intersection of nanodiamonds, 3D printing, and growth hormones in womb therapy is becoming more of a reality. We’re striving to develop a delivery system that can safely disintegrate as the baby grows, which is not an insurmountable challenge. Our goal is to offer this advanced treatment to families within the next five years.”
commenting on the intricate relationship between VEGF and bodily growth, Professor Paolo De Coppi from GOSH emphasized the delicacy required when deploying such a powerful hormone. “VEGF can facilitate the creation of new blood vessels and enhance muscle development, yet when mismanaged or administered excessively, it poses health risks. The nanodiamond delivery system is vital for maintaining precision and control over VEGF delivery, ensuring it’s administered exactly where, when, and how it should be,” he stated.
Similarly, Professor Jan Deprest, a fetal surgeon at UCLH and KU Leuven, underscored the dual advancements emerging from this study. First, the treatment has the potential to amplify the effects of currently available surgical interventions like FETO. Second, the team has demonstrated the feasibility of laboratory-created lung models derived from fetal tissues, allowing researchers to test therapeutic interventions aimed at saving an infant’s life post-delivery.
Families grappling with CDH are directly impacted by these pioneering developments. GOSH currently manages the care of approximately one child per month dealing with this serious condition. The hospital collaborates closely with UCLH to offer comprehensive services, including consultations, counseling, and if necessary, the FETO procedure.
Personal stories, like that of young Amelia, illustrate the human stakes underlying the research. Diagnosed shortly after birth, Amelia’s initial prognosis was grave due to her CDH, a condition discovered while she was still in utero. The swift actions of the medical team at GOSH provided critical support, enabling Amelia to breathe independently sooner than expected—a testament to the advancements in the care protocols for CDH.
Despite Amelia’s impressive recovery, she suffered a relapse of her condition, an unfortunate side effect experienced by up to 20% of children with CDH. Her mother, Georgia Turner, recounted the anxious moments leading to Amelia’s return to GOSH for further surgery. “While it was concerning that Amelia didn’t display obvious signs of relapse, the ongoing research provides hope for more successful and less invasive treatments in the future,” she remarked.
The research described here has received significant backing, notably from the National Institute for Health and Care Research (NIHR), which supports various initiatives through the NIHR GOSH Biomedical Research Centre. Organizations such as the Wellcome Trust, GOSH Charity, and the BREATH Consortium have also contributed funding, highlighting the collaborative effort behind advancing treatment options for this rare yet grave condition.
As the study governing prenatal VEGF nanodelivery progresses, its implications could be far-reaching, offering a promising new avenue for tackling congenital diaphragmatic hernia. The dedication from these diverse teams reinforces the value of international collaboration in addressing complex medical challenges, particularly those related to rare diseases.
With continual advancements and an interdisciplinary approach, researchers remain hopeful that innovations like this one may soon lead to phenomenal breakthroughs in prenatal medicine and the overall survival rates for children suffering from congenital conditions.
Subject of Research: Animals
Article Title: Prenatal VEGF Nanodelivery Reverses Congenital Diaphragmatic Hernia–associated Pulmonary Abnormalities
News Publication Date: Not specified
Web References: Not specified
References: Not specified
Image Credits: Not specified
